

# BeOne and EU HTA

## Key learnings and insights to date

Marlene Gyldmark, EU HTA  
Silvy Mardiguian, Head EU HEOR  
6 November 2025



# EU HTA readiness, 2025

---

## **Context:**

BeOne Medicines is a mid-sized company that has experienced rapid growth, evolving into a successful global oncology player. While not a large pharmaceutical company, BeOne has built a strong international presence and reputation through its focused strategy and swift expansion.

1. Initial low level of awareness of «What is the EU HTA regulation» and potential impact on the company
2. High level of interest and willingness to learn and adapt
3. Kick-off of EU HTA readiness project at the same time as kicking off our first JCA dossier in Q4 2024



# Key learnings and call for **dialogue, partnership and good common sense for innovation to reach the patients**

---

Start early, at least 2 years prior to EMA submission

Predicting PICO is easy, but where to focus efforts is a headache

- Need to trade-off generating evidence at risk vs evidence that may not be needed
- More transparency needed on how PICOs are consolidated, preferably in a scientific way

Need for useful engagement between assessors/JCA SG and HTDs

Stakeholder input into the JCA and the JSC is currently a blind spot



# Thanks

